Senseonics’ Eversense 33 CGM system expands Medicare coverage

Senseonics and Ascensia Diabetes Care, a global diabetes care company, announced that Medicare has significantly expanded access to the Eversense E3 CGM System, a continuous glucose monitoring designed by Senseonics and brought to people by Ascensia. The Eversense E3 CGM System offers people a fully implantable option that is differentiated from traditional CGMs, with the implementation of Local Coverage Determinations providing access to implantable CGM for basal only patients, by the first three Medicare Administrative Contractors, or MACs. Medicare coverage has been expanded for implantable CGMs to include all people with diabetes using insulin, removing the previous requirement for multiple insulin administrations per day. The new policy has also been updated to cover non-insulin-users who have a history of problematic hypoglycemia. Noridian, Palmetto and National Government Services are the first three MACs to publish final local coverage determinations. The earliest MAC expansion becomes effective on February 25, 2024 and the companies expect the remaining MACs to finalize their expansion in the near future.